A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Public ClinicalTrials.gov record NCT01381874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Study identification
- NCT ID
- NCT01381874
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 297 participants
Conditions and interventions
Conditions
Interventions
- Abiraterone acetate + Prednisone or Prednisolone Drug
- Abiraterone acetate + Prednisone/ Prednisolone + Exemestane Drug
- Exemestane Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 23, 2011
- Primary completion
- Jul 27, 2014
- Completion
- Aug 7, 2018
- Last update posted
- Apr 10, 2019
2011 – 2018
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Muscle Shoals | Alabama | — | — |
| Not listed | Fresno | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Monterey | California | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Waterville | Maine | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Henderson | Nevada | — | — |
| Not listed | East Syracuse | New York | — | — |
| Not listed | Johnson City | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Fargo | North Dakota | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Kettering | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Sioux Falls | South Dakota | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | El Paso | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Tyler | Texas | — | — |
| Not listed | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01381874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 10, 2019 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01381874 live on ClinicalTrials.gov.